Xencor's CEO Discusses Q4 2013 Results - Earnings Call Transcript Seeking Alpha So that's a potential significant differentiator for safety purposes from cytotoxic B-cell antibodies that are currently used in autoimmune disease such as rituximab. Now, our partner Amgen has an option to acquire the exclusive worldwide license to ... |
